ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017
December 13 2017 - 4:00PM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, today announced that its 2017 Annual
Meeting of Stockholders ("Annual Meeting"), scheduled for
Wednesday, December 13, 2017, was convened and adjourned, without
any business being conducted, due to lack of the requisite quorum.
The Annual Meeting has been adjourned to 9:00 AM local time on
December 21, 2017 at the Company’s offices located at 399 Thornall
Street, First Floor, Edison, New Jersey 08837, to allow additional
time for stockholders to vote on the proposals set forth in
ContraVir’s definitive proxy statement on Schedule 14A, filed with
the Securities and Exchange Commission on October 27, 2017.
The record date for the Annual Meeting remains October 27, 2017.
Stockholders who have previously submitted their proxy or otherwise
voted and who do not want to change their vote need not take any
action. Company stockholders as of the October 27, 2017 record date
can vote, even if they have subsequently sold their shares. The
Company’s board of directors and management respectfully request
all such holders as of the record date to please vote your proxies
as soon as possible.
No changes have been made in the proposals to be voted on by
stockholders at the Annual Meeting. The Company strongly advises
all of its stockholders to read the proxy statement and other proxy
materials relating to the Annual Meeting because they contain
important information. Such proxy materials are available at no
charge on the Securities and Exchange Commission's website
at www.sec.gov. In addition, copies of the Proxy Statement and
other documents may be obtained free of charge by accessing
www.pstvote.com/contravir2017 or by contacting the Company’s
Corporate Secretary at 732-902-4000 or by mail to Corporate
Secretary, ContraVir Pharmaceuticals, Inc., 399 Thornall Street,
First Floor, Edison, New Jersey 08837.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused
by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. In vitro and in vivo studies have thus far demonstrated that
CRV431 reduces HBV DNA and other viral proteins, including surface
antigen (HBsAg). For more information
visit www.contravir.com.
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on
ContraVir's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2017 and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2023 to Apr 2024